The medicine everyone wants — and nobody can sell.
Yezz tracks Eli Lilly's triple-agonist injection through the trials and the UK regulatory pathway. One rule, site-wide: there is nothing here to buy, because there is nothing to buy anywhere.
Independently written · Last reviewed: · editorial policy
28.3%
Average weight loss in TRIUMPH-1
12 mg dose, 80 weeks. Topline, May 2026.
45.3%
Lost at least 30% of body weight
12 mg dose — bariatric-surgery territory.
0
Countries where it is approved
No MHRA authorisation. No FDA approval. Anywhere.
2028
Earliest realistic UK availability
Private pharmacies. NHS access: later still.
The strongest weight-loss data in history meets zero legal supply.
01
The data
TRIUMPH-1, TRIUMPH-2, TRIUMPH-3 and four more trials produced numbers no medicine in this class has touched. The science is real and it is extraordinary.
02
The law
No marketing authorisation in the UK, the US or anywhere. No brand name, no price, no pharmacy stock. Lilly itself cannot sell a single pen yet.
03
The scam gap
Between enormous demand and zero supply sits a thriving illegal market of “research peptides” — unknown substances sold to hopeful people.
Everything about retatrutide, properly sourced.
If you can buy it, it is not retatrutide.
Vials, pens and “research peptides” sold online are unlicensed products of unknown content and purity — and supplying them for human use is illegal in the UK. The one-line test settles every listing: a genuine product cannot be for sale before authorisation.
The full warning — red flags and what to do →£0
is the only honest price on the internet for retatrutide.
No price has been announced in any country. Any number on a sales page is invented — usually as a hook. Expect a premium launch price if it is ever authorised; ignore everything until then.
Already looking for treatment now?
Retatrutide is years from UK pharmacy shelves, but authorised options exist today — the safe route is always the same: a clinical consultation with a regulated provider, and dispensing by a GPhC-registered pharmacy you have verified yourself. Our independent sister sites track them:
- Mounjaro in the UK — the strongest authorised injection; live prices at monj.co.uk.
- Wegovy in the UK — regulated providers listed at igovy.co.uk.
- The Wegovy pill — oral semaglutide; regulated providers at ogovy.co.uk.
- Foundayo — the rule-free daily tablet; regulated providers at dayo.co.uk.
Whatever you choose, check the pharmacy on the official GPhC register first — and treat any seller of unapproved “retatrutide” as the scam it is.
Sources
Every factual claim on this page traces to one of these primary sources. We link out so you can check the original.
- 1.Eli Lilly — TRIUMPH-1 topline results (21 May 2026) — curated history of retatrutide development and regulatory status, including Lilly press releases
- 2.Retatrutide UK: availability, trial results and legal status — independent UK summary, updated July 2026
- 3.Retatrutide FDA approval timeline 2026–2028 — milestone tracker with ClinicalTrials.gov registrations
- 4.MHRA products register — official UK register — no retatrutide marketing authorisation is listed
- 5.Jastreboff et al., New England Journal of Medicine (2023) — Phase 2 obesity trial results